Literature DB >> 30258023

Psychiatric disorders in C9orf72 kindreds: Study of 1,414 family members.

Emma M Devenney1, Rebekah M Ahmed2, Glenda Halliday2, Olivier Piguet2, Matthew C Kiernan2, John R Hodges2.   

Abstract

OBJECTIVE: The aim of this study was to determine in a systematic manner if the C9orf72 phenotype might extend beyond frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) to include psychiatric disease.
METHODS: A validated semistructured family history interview was conducted in a large cohort of patients with FTD and ALS (n = 89), with and without the C9orf72 expansion (n = 29 and n = 60, respectively), encompassing 1,414 first- and second-degree relatives. Statistical analyses used both the hazard ratio (HR) and the relative risk ratio to determine the risk profiles within families.
RESULTS: A significant HR of 4.9 (95% confidence interval [CI]: 1.9-13.9, p = 0.003) confirmed a higher probability of developing schizophrenia for relatives of C9orf72 carriers compared with noncarriers. In addition, 8 relatives of C9orf72 carriers experienced an episode of late-onset psychosis unrelated to schizophrenia, in comparison to one noncarrier (HR = 17.9, 95% CI: 2.2-143.2, p = 0.007). The probability of suicide was also significantly higher for family members of C9orf72 carriers (HR = 2.7, 95% CI: 1.2-6.2, p = 0.02). An HR of 2.7 (95% CI: 1.1-6.9, p = 0.03) indicated a higher probability of autism spectrum disorder (ASD) in family members of C9orf72 carriers, and this risk extended to FTD. Furthermore, there was a positive association between psychosis in probands and mental health disorders, including ASD in their family members (p = 0.04).
CONCLUSION: Overall, the results from this study suggest that a psychiatric phenotype exists within C9orf72 kindreds. Further studies should attempt to delineate the risk of psychiatric disorders in C9orf72 kindreds to aid in clinical decision making, particularly regarding genetic counseling, through collaborations between neurology and psychiatry.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30258023     DOI: 10.1212/WNL.0000000000006344

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

Review 1.  Behavioural Variant Frontotemporal Dementia: Recent Advances in the Diagnosis and Understanding of the Disorder.

Authors:  Rebekah M Ahmed; John R Hodges; Olivier Piguet
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 3.  Links Between the C9orf72 Repeat Expansion and Psychiatric Symptoms.

Authors:  Hannah E Silverman; Jill S Goldman; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

4.  New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.

Authors:  Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton
Journal:  Alzheimers Dement       Date:  2020-01-06       Impact factor: 21.566

Review 5.  Bipolar Disorder Among Patients Diagnosed With Frontotemporal Dementia.

Authors:  Mario F Mendez; Leila Parand; Golnoush Akhlaghipour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-06-05       Impact factor: 2.198

Review 6.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

7.  Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond.

Authors:  Dario Saracino; Isabelle Le Ber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

Review 9.  Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders.

Authors:  Simon Ducharme; Annemiek Dols; Robert Laforce; Emma Devenney; Fiona Kumfor; Jan van den Stock; Caroline Dallaire-Théroux; Harro Seelaar; Flora Gossink; Everard Vijverberg; Edward Huey; Mathieu Vandenbulcke; Mario Masellis; Calvin Trieu; Chiadi Onyike; Paulo Caramelli; Leonardo Cruz de Souza; Alexander Santillo; Maria Landqvist Waldö; Ramon Landin-Romero; Olivier Piguet; Wendy Kelso; Dhamidhu Eratne; Dennis Velakoulis; Manabu Ikeda; David Perry; Peter Pressman; Bradley Boeve; Rik Vandenberghe; Mario Mendez; Carole Azuar; Richard Levy; Isabelle Le Ber; Sandra Baez; Alan Lerner; Ratnavalli Ellajosyula; Florence Pasquier; Daniela Galimberti; Elio Scarpini; John van Swieten; Michael Hornberger; Howard Rosen; John Hodges; Janine Diehl-Schmid; Yolande Pijnenburg
Journal:  Brain       Date:  2020-06-01       Impact factor: 13.501

10.  Schizotypal traits across the amyotrophic lateral sclerosis-frontotemporal dementia spectrum: pathomechanistic insights.

Authors:  Nga Yan Tse; Sicong Tu; Yu Chen; Jashelle Caga; Carol Dobson-Stone; John B Kwok; Glenda M Halliday; Rebekah M Ahmed; John R Hodges; Olivier Piguet; Matthew C Kiernan; Emma M Devenney
Journal:  J Neurol       Date:  2022-03-13       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.